

Natco Pharma Limited Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243 CIN : L24230TG1981PLC003201, www.natcopharma.co.in

September 8, 2023

Corporate Relationship Department
M/s. BSE Ltd.
Dalal Street, Fort
<u>Mumbai 400 001</u>

Manager – Listing M/s. National Stock Exchange of India Ltd "Exchange Plaza", Bandra – Kurla Complex Bandra (E) <u>Mumbai 400 051</u>

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir/Madam,

Please find enclose herewith the disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for your information.

Thanking you,

Yours faithfully For NATCO Pharma Limited

Ch. Venkat Ramesh Company Secretary & Compliance Officer



Ref: PR/06/2023-24

Press Release

Hyderabad, 8th September, 2023

LEGAL UPDATE

NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) would like to update that Celgene Corporation, Bristol Myers Squibb, Breckenridge Pharmaceutical Inc. and Natco Pharma Ltd. have been named defendants along with others in an antitrust lawsuit in the US by Louisiana Health Service & Indemnity Company D/B/A Blue Cross and Blue Shield of Losisiana and HMO Louisiana Inc., regarding Pomalidomide (POMALYST).

Natco believes this matter is without merit. Breckenridge is the ANDA holder and distribution partner for the generic product in the US.

For NATCO Pharma Limited

Ch. Venkat Ramesh Company Secretary & Compliance Officer